JP2008511637A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008511637A5 JP2008511637A5 JP2007530195A JP2007530195A JP2008511637A5 JP 2008511637 A5 JP2008511637 A5 JP 2008511637A5 JP 2007530195 A JP2007530195 A JP 2007530195A JP 2007530195 A JP2007530195 A JP 2007530195A JP 2008511637 A5 JP2008511637 A5 JP 2008511637A5
- Authority
- JP
- Japan
- Prior art keywords
- lung
- active agent
- respirable
- active
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 24
- 210000004072 lung Anatomy 0.000 claims description 18
- 229940121375 antifungal agent Drugs 0.000 claims description 12
- 239000003429 antifungal agent Substances 0.000 claims description 12
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 7
- 229960004130 itraconazole Drugs 0.000 claims description 7
- 229960003483 oxiconazole Drugs 0.000 claims description 7
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 claims description 7
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 6
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 claims description 6
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 claims description 6
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims description 6
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 6
- 229960002206 bifonazole Drugs 0.000 claims description 6
- 229960004022 clotrimazole Drugs 0.000 claims description 6
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 6
- 229960003913 econazole Drugs 0.000 claims description 6
- 229960004884 fluconazole Drugs 0.000 claims description 6
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 6
- 229960004413 flucytosine Drugs 0.000 claims description 6
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims description 6
- 229960004125 ketoconazole Drugs 0.000 claims description 6
- 229960002509 miconazole Drugs 0.000 claims description 6
- 229960003255 natamycin Drugs 0.000 claims description 6
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 claims description 6
- 235000010298 natamycin Nutrition 0.000 claims description 6
- 239000004311 natamycin Substances 0.000 claims description 6
- 229960002607 sulconazole Drugs 0.000 claims description 6
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 claims description 6
- 229960004880 tolnaftate Drugs 0.000 claims description 6
- 208000031888 Mycoses Diseases 0.000 claims description 4
- 239000002184 metal Chemical class 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims 16
- 229940079593 drug Drugs 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 12
- -1 rubconazole Chemical compound 0.000 claims 10
- 239000002245 particle Substances 0.000 claims 7
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 claims 5
- 239000003960 organic solvent Substances 0.000 claims 5
- 229960000580 terconazole Drugs 0.000 claims 5
- 239000007864 aqueous solution Substances 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000008186 active pharmaceutical agent Substances 0.000 claims 2
- 239000012296 anti-solvent Substances 0.000 claims 2
- 150000004696 coordination complex Chemical class 0.000 claims 2
- 229940088679 drug related substance Drugs 0.000 claims 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 238000004064 recycling Methods 0.000 claims 2
- 239000002002 slurry Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 238000005507 spraying Methods 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 150000003851 azoles Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960001589 posaconazole Drugs 0.000 claims 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 description 1
- 229960003204 amorolfine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960001274 fenticonazole Drugs 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60517904P | 2004-08-27 | 2004-08-27 | |
| PCT/US2005/030543 WO2006026502A1 (en) | 2004-08-27 | 2005-08-26 | Enhanced delivery of drug compositions to treat life threatening infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008511637A JP2008511637A (ja) | 2008-04-17 |
| JP2008511637A5 true JP2008511637A5 (enExample) | 2008-10-23 |
Family
ID=35520830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007530195A Pending JP2008511637A (ja) | 2004-08-27 | 2005-08-26 | 致命的な感染症を治療する薬剤組成物の増強された供給 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US9061027B2 (enExample) |
| EP (1) | EP1789018A1 (enExample) |
| JP (1) | JP2008511637A (enExample) |
| WO (1) | WO2006026502A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0327723D0 (en) | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| WO2008127746A1 (en) | 2007-01-10 | 2008-10-23 | Board Of Regents The University Of Texas System | Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery |
| NO2252275T3 (enExample) | 2008-02-13 | 2018-04-28 | ||
| EP2601973A1 (en) | 2011-12-09 | 2013-06-12 | Laboratoires SMB SA | Dry powder formulation of azole derivative for inhalation |
| WO2014106727A1 (en) * | 2013-01-03 | 2014-07-10 | Vectura Limited | Inhaler and formulation |
| WO2014186754A2 (en) | 2013-05-16 | 2014-11-20 | Board Of Regents The University Of Texas System | Dry solid aluminum adjuvant-containing vaccines and related methods thereof |
| MX2018002586A (es) | 2015-09-01 | 2020-11-24 | First Wave Bio Inc | Composiciones para usarse en el tratamiento de afecciones asociadas a una repsuesta inflamatoria anómala. |
| RU2766086C2 (ru) | 2016-10-14 | 2022-02-07 | Пулматрикс Оперэйтинг Компани, Инк. | Противогрибковые сухие порошки |
| CA3083953A1 (en) | 2017-12-11 | 2019-06-20 | Board Of Regents, The University Of Texas System | Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration |
| US10993890B2 (en) | 2018-03-15 | 2021-05-04 | Pelli Skin Co., Llc | Antifungal solution and foot wipe |
| US20210145739A1 (en) * | 2018-04-18 | 2021-05-20 | Pulmatrix Operating Company, Inc. | Antifungal formulations for pulmonary administration comprising itraconazole |
| MX2021000796A (es) * | 2018-07-24 | 2021-06-15 | Univ Texas | Composiciones de partículas terapéuticamente activas con superficie modificada por congelación ultra-rápida. |
| US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| WO2021188564A1 (en) | 2020-03-16 | 2021-09-23 | First Wave Bio, Inc. | Methods of treating covid-19 with a niclosamide compound |
| CN111568878B (zh) * | 2020-05-22 | 2022-03-25 | 浙江圣兆药物科技股份有限公司 | 一种基于液下气流喷雾技术制备多肽类药物微球的方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4950477A (en) | 1988-08-23 | 1990-08-21 | Memorial Hospital For Cancer And Allied Dieseas | Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes |
| GB8908250D0 (en) | 1989-04-12 | 1989-05-24 | Fisons Plc | Formulations |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| EP0810853B1 (en) | 1995-02-24 | 2004-08-25 | Elan Pharma International Limited | Aerosols containing nanoparticle dispersions |
| US5539021A (en) | 1995-06-05 | 1996-07-23 | The Dow Chemical Company | Process for preparing high internal phase ratio emulsions and latexes derived thereof |
| US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| US6630169B1 (en) * | 1999-03-31 | 2003-10-07 | Nektar Therapeutics | Particulate delivery systems and methods of use |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| US6756062B2 (en) * | 2000-11-03 | 2004-06-29 | Board Of Regents University Of Texas System | Preparation of drug particles using evaporation precipitation into aqueous solutions |
| AU2002245181B2 (en) * | 2000-12-21 | 2006-06-29 | Nektar Therapeutics | Pulmonary delivery of polyene antifungal agents |
| US20040022862A1 (en) | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
| US20030072807A1 (en) | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
| JP2004517699A (ja) | 2001-01-30 | 2004-06-17 | ボード オブ リージェンツ ユニバーシティ オブ テキサス システム | 液体中への噴霧凍結によるナノ粒子およびミクロ粒子の製造方法 |
| WO2003032951A1 (en) | 2001-08-29 | 2003-04-24 | Dow Global Technologies Inc. | A process for preparing crystalline drug particles by means of precipitation |
| DE10145361A1 (de) * | 2001-09-14 | 2003-04-03 | Pari Gmbh | Verfahren zur Herstellung von flüssigen, sterilen Zubereitungen zur Inhalation |
| US7112340B2 (en) | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
| CA2483218C (en) * | 2002-04-25 | 2012-07-10 | Nektar Therapeutics Uk Ltd | Particulate materials |
| AUPS333302A0 (en) * | 2002-07-02 | 2002-07-25 | Fultec Pty Ltd | A protection and indication circuit |
| EP1556018A1 (en) * | 2002-09-30 | 2005-07-27 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
| US20040121003A1 (en) * | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
| AU2003302274A1 (en) * | 2002-12-31 | 2004-07-29 | Novartis Ag | Aerosolizable pharmaceutical formulation for fungal infection therapy |
| JP2006513236A (ja) | 2002-12-31 | 2006-04-20 | ネクター セラピューティクス | 不溶性活性物質を伴う医薬製剤 |
| JP4933732B2 (ja) | 2003-01-15 | 2012-05-16 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 低温表面上で凍結させることによって得られる薬物粒子 |
| US9192578B2 (en) | 2008-08-20 | 2015-11-24 | Board Of Regents, The University Of Texas System | Hot-melt extrusion of modified release multi-particulates |
-
2005
- 2005-08-26 EP EP05804416A patent/EP1789018A1/en not_active Withdrawn
- 2005-08-26 WO PCT/US2005/030543 patent/WO2006026502A1/en not_active Ceased
- 2005-08-26 JP JP2007530195A patent/JP2008511637A/ja active Pending
- 2005-08-26 US US11/660,012 patent/US9061027B2/en active Active
-
2015
- 2015-05-15 US US14/713,156 patent/US9724344B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6904929B2 (ja) | エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用 | |
| JP7334145B2 (ja) | 鼻腔内送達用乾燥粉末組成物 | |
| JP2008511637A5 (enExample) | ||
| CN105188757B (zh) | 多孔载体颗粒和微粒化药物的可吸入团聚物 | |
| US20220184080A1 (en) | Nebulized imatinib formulations, manufacture, and uses thereof | |
| JP2003521459A (ja) | 医薬用エーロゾル製剤 | |
| JP2002541183A (ja) | 医薬用エアゾール製剤 | |
| JP2002526459A (ja) | 医療用エアゾ−ル製剤 | |
| JP2002529396A (ja) | 超微粒子薬剤を含んで成るエーロゾル | |
| JP2002506017A (ja) | ニコチン吸入器 | |
| JP2002527473A (ja) | フォルモテロールを含む貯蔵可能な活性物質濃縮物 | |
| CN101083979A (zh) | 药物制剂 | |
| AU2003273273B2 (en) | Trospium containing compositions | |
| JP2009539958A (ja) | 安定なエアロゾル医薬製剤 | |
| JP2002538855A (ja) | リポソーム粉末エアロゾルの肺適用のための圧縮空気吸入器及びそのために適した粉末エアロゾル | |
| CN102905694B (zh) | 吸入溶液 | |
| JP2008511637A (ja) | 致命的な感染症を治療する薬剤組成物の増強された供給 | |
| JP6503043B2 (ja) | 新規噴射剤含有チオトロピウム製剤 | |
| AU2019256453B2 (en) | Methods of treating fungal infections | |
| JP2013539784A (ja) | 嚢胞性線維症の吸入デヌホソルでの治療方法 | |
| EP4333853A1 (en) | Methods for treating a pulmonary disease with an alk-5 (tgf beta r1) inhibitor | |
| JP5437543B2 (ja) | 喘息検出用製剤 | |
| KR20220080127A (ko) | 폐 질환을 위한 흡입 가능한 건조 분말 조성물 | |
| Sallam | Recent advances in the formulation development of inhalational dosage forms | |
| JP2005206485A (ja) | イソキノリンスルホンアミド誘導体を含有する医薬 |